Kim Vettenranta - Concepedia

Author

Kim Vettenranta

Also Known As

Ingo Muller, Jesper Brok, K VETTENRANTA, K Vettenranta, K. Vettenranta, KIM VETTENRANTA, Kim K. Vettenranta, Kim Vettenranta, Vettenranta K, Vettenranta, Kim

275

Publications

6.1K

Citations

H-Index

154

Concepts

All Affiliations

University of Helsinki Helsinki University Hospital Rigshospitalet Helsinki Children's Hospital

About

Kim Vettenranta is an author at University of Helsinki specializing in medicine, hematology, and pediatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	55	2.6K
2	Health Sciences	11	12	759
3	Public Health	6	6	224
4	Education	1	1	28
5	Natural Sciences	1	1	35

Kim Vettenranta

111

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia N. Toft, Henrik Birgens, Jonas Abrahamsson, Leukemia Hematological MalignancyNopho All2008 TreatmentOncologyMalignant Blood DisorderHematology	2017	401
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study Christina Peters, Jean‐Hugues Dalle, Franco Locatelli, Journal of Clinical Oncology	2020	309
Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005 Maurizio Aricò, Martin Schrappe, Stephen P. Hunger, Journal of Clinical Oncology	2010	243
Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years Liisa Hovi, UM Saarinen‐Pihkala, Kim Vettenranta, Bone Marrow Transplantation TransplantationMarrow TransplantationPediatric HematologySingle Center ExperienceHematology	2000	184
Age- and Sex-Specific Incidence of Childhood Leukemia by Immunophenotype in the Nordic Countries Lisa Lyngsie Hjalgrim, Klaus Rostgaard, Kjeld Schmiegelow, JNCI Journal of the National Cancer Institute	2003	150
Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study Kjeld Schmiegelow, Ibrahim Al-Modhwahi, Mette Klarskov Andersen, Blood	2009	146
Cardiac Magnetic Resonance Imaging in the Evaluation of the Late Effects of Anthracyclines Among Long-Term Survivors of Childhood Cancer Kaisa Ylänen, Tuija Poutanen, Päivi Savikurki-Heikkilä, Journal of the American College of Cardiology OncologyOncologic ImagingLate EffectsLong-term SurvivorsMedicine	2013	139
Risk group assignment differs for children and adults 1–45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL‐2008 protocol Nina Toft, Henrik Birgens, Jonas Abrahamsson, European Journal Of Haematology	2013	137
Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases René Martin Linka, Sarah L. Risse, K. Bienemann, Leukemia Primary ImmunodeficiencyImmunologyEbv-associated Lymphoproliferative DiseasesPathologyAutoimmunity	2012	132
Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study Kjeld Schmiegelow, Erik Forestier, Jakob Kristinsson, Leukemia Hematological MalignancyThiopurine Methyltransferase ActivityPediatric HematologyMedicineHematology	2008	123

Page 1